NCT04971226 2026-03-10
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Novartis
Phase 3 Active not recruiting
Clinical Trials
36 trialsNCT03007147 2026-02-23
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Children's Oncology Group
Phase 3 Active not recruiting
NCT02881086 2025-12-16
Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment
Goethe University
Phase 3 Completed
NCT04307576 2025-08-28
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
Karolinska University Hospital
Phase 3 Recruiting
NCT05413915 2025-05-21
Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML
Sir Mortimer B. Davis - Jewish General Hospital
Phase 3 Active not recruiting
NCT04722848 2025-01-23
Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 3 Active not recruiting
NCT03722420 2024-10-28
Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)
Il-Yang Pharm. Co., Ltd.
Phase 3 Active not recruiting
NCT02326311 2024-08-13
Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 3 Completed
NCT02130557 2021-05-18
A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Pfizer
Phase 3 Completed
NCT01827930 2020-12-31
MIM
Institut Bergonié
Phase 3 Terminated
NCT00137111 2020-09-11
Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Phase 3 Completed
NCT00219739 2020-04-13
SPIRIT
Poitiers University Hospital
Phase 3 Completed
NCT02174445 2019-12-02
DECLINE
University Hospital Freiburg
Phase 3 Terminated
NCT02272777 2019-08-19
A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase
Novartis
Phase 3 Completed
NCT00574873 2019-01-08
Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML
Pfizer
Phase 3 Completed
NCT00055874 2018-05-03
Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Heidelberg University
Phase 3 Completed
NCT01460693 2018-04-24
SPIRIT2
Newcastle University
Phase 3 Completed
NCT00481247 2017-02-15
DASISION
Bristol-Myers Squibb
Phase 3 Completed
NCT00760877 2016-11-08
Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)
Novartis
Phase 3 Completed
NCT00327678 2016-06-27
Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults
Assistance Publique - Hôpitaux de Paris
Phase 3 Completed
NCT00050531 2016-05-11
High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)
M.D. Anderson Cancer Center
Phase 3 Completed
NCT01275196 2016-04-08
Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients
Novartis
Phase 3 Completed
NCT01511289 2016-02-24
Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients
Il-Yang Pharm. Co., Ltd.
Phase 3 Completed
NCT00802841 2015-11-16
LASOR
Novartis
Phase 3 Completed
NCT01650805 2014-11-17
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Ariad Pharmaceuticals
Phase 3 Terminated
NCT00022737 2014-02-27
Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 3 Completed
NCT01400074 2014-01-13
RE-NICE
Seoul St. Mary's Hospital
Phase 3 Unknown
NCT01819389 2014-01-07
Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance
Hospital Universitario Dr. Jose E. Gonzalez
Phase 3 Completed
NCT00333840 2013-10-14
Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
Novartis
Phase 3 Completed
NCT00006343 2013-01-03
STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
Novartis
Phase 3 Completed
NCT00124748 2012-02-03
TOPS
Novartis
Phase 3 Terminated
NCT00237120 2009-11-23
Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)
Novartis
Phase 3 Completed
NCT00362466 2009-11-20
A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy
Bristol-Myers Squibb
Phase 3 Terminated
NCT00297570 2007-10-10
Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy
Sheba Medical Center
Phase 3 Unknown
NCT00514488 2007-08-10
CML022
University of Bologna
Phase 3 Completed
NCT00327262 2006-06-20
Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase
Central European Leukemia Study Group
Phase 3 Unknown